Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma | Zendy

John K. Lin | Zendy; Lori Muffly | Zendy; Michael A. Spinner | Zendy; James I. Barnes | Zendy; Douglas K Owens | Zendy; Jeremy D. GoldhaberFiebert | Zendy

Open Access

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma

Author(s) -

John K. Lin,

Lori Muffly,

Michael A. Spinner,

James I. Barnes,

Douglas K Owens,

Jeremy D. GoldhaberFiebert

Publication year - 2019

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.18.02079

Subject(s) - medicine , quality adjusted life year , life expectancy , oncology , cost effectiveness , chemoimmunotherapy , chimeric antigen receptor , pediatrics , lymphoma , rituximab , immunotherapy , population , cancer , risk analysis (engineering) , environmental health

Two anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies are approved for diffuse large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel; each costs $373,000. We evaluated their cost effectiveness.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research